Transcription
Hi, this is Derek Mueller, PA from Detroit, Michigan, coming to you from ACR 2026 in Orlando, Florida. I'd like to talk to you about an interesting abstract, abstract number 1881. And this is looking at the efficacy and safety of gevokizumab — actually, let me revisit — this is looking at the efficacy and safety of gooflicase in familial Mediterranean fever or FMF.
Um, so why am I talking about FMF and new molecules? Well, depending on where you are in the country, familial Mediterranean fever can feel like an orphan disease or it can be a relatively common condition that you may encounter. Uh, in my home state of Michigan, specifically in southeast Michigan, we have the highest concentration of Iraqis in the United States. So, again, depending on where you practice, uh, it might pay off to be up to date on the latest and greatest in this disease state.
And as we know with the treatment of FMF, um, the main stay of treatment remains colchicine therapy. However, for various reasons, either due to intolerance or lack of efficacy, uh, second line treatments are sometimes required in these patients and our second line options are relatively limited at this point in time. However, this uh, this novel molecule looks to add to the armamentarium of therapies that can be utilized as second line therapy in FMF.
Uh, so, goflikicept, or I'll call it Goff for now. Um, this molecule demonstrates very high binding affinity for the interleukin-1 beta cytokine that we feel is the dominant driver of inflammatory disease uh, in FMF. Uh, however, unlike other available IL-1 agents, this molecule also has some binding affinity for other members of the IL-1 superfamily that includes IL-1 alpha and the IL-1 receptor antagonist.
Um, so this was a double-blind, placebo-controlled randomized trial that compared the molecule Goff to placebo in patients with active FMF who had failed colchicine due to intolerance or inefficacy. Uh, this was a relatively small trial — only 33 patients with FMF. Um, those who received treatment with the molecule received a loading dose of 160 milligrams injected subQ on day zero. A week later, they were given another dose of 80 milligrams. The following week, uh, another 80 milligrams, and then they were treated with 80 milligrams Q2 weeks. Again, that was versus placebo.
And the primary endpoint of the study was complete response. And in FMF, the measurement of complete response here is resolution of an attack as well as no new flare through the study period, which was 16 weeks. And just for a frame of reference, a flare definition in FMF is defined as a patient global reported symptom score of greater than or equal to two as well as an increase of C-reactive protein from baseline. And there were some secondary endpoints that were analyzed here — some things that are relevant in the world of FMF, including measurement of serum amyloid A, um, and then some quality of life measures uh, by SF-12.
Uh, the results — 29 patients completed this study, and at 16 weeks the primary endpoint was met. Um, complete response in 68% of patients on Goff versus 11% in placebo. Secondary analyses including quality of life measures numerically did favor the uh, treatment arm. As far as safety goes, there were some non-serious infections reported, headaches, elevated LFTs, and only one safety event resulted in discontinuation of the active drug.
So, limitations — this is certainly a small study during a relatively short period of time. So we'd certainly want to understand uh, the longevity of this product when used in this refractory FMF cohort. Uh, but moving forward, this really could expand the options for these specific patients um, and add to the toolkit of what we have available in refractory FMF. Uh, and currently, just out of interest, this is a molecule that's already approved in the Russian Federation. Thank you.
Um, so why am I talking about FMF and new molecules? Well, depending on where you are in the country, familial Mediterranean fever can feel like an orphan disease or it can be a relatively common condition that you may encounter. Uh, in my home state of Michigan, specifically in southeast Michigan, we have the highest concentration of Iraqis in the United States. So, again, depending on where you practice, uh, it might pay off to be up to date on the latest and greatest in this disease state.
And as we know with the treatment of FMF, um, the main stay of treatment remains colchicine therapy. However, for various reasons, either due to intolerance or lack of efficacy, uh, second line treatments are sometimes required in these patients and our second line options are relatively limited at this point in time. However, this uh, this novel molecule looks to add to the armamentarium of therapies that can be utilized as second line therapy in FMF.
Uh, so, goflikicept, or I'll call it Goff for now. Um, this molecule demonstrates very high binding affinity for the interleukin-1 beta cytokine that we feel is the dominant driver of inflammatory disease uh, in FMF. Uh, however, unlike other available IL-1 agents, this molecule also has some binding affinity for other members of the IL-1 superfamily that includes IL-1 alpha and the IL-1 receptor antagonist.
Um, so this was a double-blind, placebo-controlled randomized trial that compared the molecule Goff to placebo in patients with active FMF who had failed colchicine due to intolerance or inefficacy. Uh, this was a relatively small trial — only 33 patients with FMF. Um, those who received treatment with the molecule received a loading dose of 160 milligrams injected subQ on day zero. A week later, they were given another dose of 80 milligrams. The following week, uh, another 80 milligrams, and then they were treated with 80 milligrams Q2 weeks. Again, that was versus placebo.
And the primary endpoint of the study was complete response. And in FMF, the measurement of complete response here is resolution of an attack as well as no new flare through the study period, which was 16 weeks. And just for a frame of reference, a flare definition in FMF is defined as a patient global reported symptom score of greater than or equal to two as well as an increase of C-reactive protein from baseline. And there were some secondary endpoints that were analyzed here — some things that are relevant in the world of FMF, including measurement of serum amyloid A, um, and then some quality of life measures uh, by SF-12.
Uh, the results — 29 patients completed this study, and at 16 weeks the primary endpoint was met. Um, complete response in 68% of patients on Goff versus 11% in placebo. Secondary analyses including quality of life measures numerically did favor the uh, treatment arm. As far as safety goes, there were some non-serious infections reported, headaches, elevated LFTs, and only one safety event resulted in discontinuation of the active drug.
So, limitations — this is certainly a small study during a relatively short period of time. So we'd certainly want to understand uh, the longevity of this product when used in this refractory FMF cohort. Uh, but moving forward, this really could expand the options for these specific patients um, and add to the toolkit of what we have available in refractory FMF. Uh, and currently, just out of interest, this is a molecule that's already approved in the Russian Federation. Thank you.
Recommended videos
-
Education/ACR/EULAR
3 x IL-23 = IL do Better (11.6.2026)
-
General Rheumatology
FDA Safety Updates from ACR 2026
-
Education/ACR/EULAR
Doubting RS3PE (8.14.2026)

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.